Browse

When the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for quick access have been stymied.

The decision to move ahead with new products in the absence of FDA authorization could spur other big manufacturers to do the same, one tobacco-nicotine expert said.

FDA granted accelerated approval to AstraZeneca's oral selective estrogen receptor degrader, Camizestrant, for a specific group of breast cancer patients. The approval was issued on Friday even th…